BioProcess International Magazine

BioProcess International™ is a monthly magazine with a targeted circulation focused on the creation, scaling, and production of biotherapeutics and biodiagnostics. Every edition delivers the latest, peer-reviewed insights to the global biotherapeutic industry, covering essential topics such as business strategies, political issues, ethical considerations, applications, products, and services necessary for effectively advancing biopharmaceuticals, vaccines, and biodiagnostics from development to manufacturing.

National, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#622151

United States

#315753

Science and Education/Biology

#735

Traffic sources

Monthly visitors

Articles

Asahi Kasei unifies bioprocess services under Life Science vertical

1 week ago | bioprocessintl.com | Shreeyashi Ojha

Tokyo-headquartered Asahi Kasei has established Asahi Kasei Life Science to operate its bioprocess businesses, effective 1 April 2025. The vertical includes Asahi Kasei’s contract research organization (CRO) testing services, provided through ViruSure (acquired in 2019) and Bionique (acquired in 2021). It also incorporates its contract development and manufacturing organization (CDMO), Bionova, which the company acquired in 2022.
Kyowa Kirin bolsters biomanufacturing footprint with $118m Japan plant

1 week ago | bioprocessintl.com | Shreeyashi Ojha

DEPOSITPHOTOS/zlatovlaska2008With an investment of ¥16.8 billion ($118 million), the 510,000 square-foot facility will use Kyowa’s antibody technology and protein engineering to manufacture drug substances. The GMP compliant plant will utilize single-use technology to reduce the risk of cross-contamination between products.
Boehringer invests $30 million into antibody drug conjugate research and development

1 week ago | bioprocessintl.com | Søren Hough

Søren Hough, Editor, Drug Modalities at Tides GlobalBoehringer invests $30 million in ADCsstock.adobe.comIn Basel, Switzerland, Boehringer Ingelheim has invested CHF 27 million ($31.5 million) in antibody drug conjugate (ADC) development by opening a new research facility dedicated to the modality. The facility will operate under Boehringer’s subsidiary company, NBE Therapeutics, which it acquired for over $1 billion in 2020.
INCOG doubles down on sterile injectables in Indiana

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

INCOG investing in Indiana DepositPhotos/gustavofrazaoThe expansion will provide device assembly capacity for autoinjectors, pens, wearable injectors, and syringe accessorizing. The site will eventually house a team of more than 350 employees. In February 2024, the contract development and manufacturing organization (CDMO) invested $75 million, adding Optima syringe and cartridge filling line to meet the burgeoning syringe and cartridge filling demand.
Biomanufacturing giant Merck KGaA slimming down French in Martillac plant due to CDMO market tensions

2 weeks ago | bioprocessintl.com | Dan Stanton

In October 2022, Germany’s Merck opened a €50 million ($55 million) plant at its Martillac site, south of Bordeaux, to support its contract development and manufacturing organization (CDMO) business. The 2,700 square-meter single-use plant has the capacity to produce commercial monoclonal antibody and recombinant protein drug substance up to the 2,000 L scale, based on single-use systems.
Big in Japan: AGC installing 5,000 L single-use bioreactors

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

The Seattle-based firm broke ground on a four-story, 20,000 square-meter facility in January 2024. With an investment of ¥ 50 billion ($325 million), the plant will deal in mammalian-based protein biologics, cell therapies, and messenger RNA (mRNA). It is expected to create 400 jobs locally.
Who’s in, who’s up, and who’s steering CDMO ships

2 weeks ago | bioprocessintl.com | Shreeyashi Ojha

Contract development and manufacturing organization (CDMO) Veranova has appointed Scott Zugel as global vice president of analytical research development operations. Zugel, a veteran with over two decades of experience, joins the Massachusetts-based firm after serving as the head of analytical development at Takeda, where he established the company’s first internal metrology team for analytical testing labs.
CDMO scale up: Resilience, Wheeler, SHL strengthen US ops

3 weeks ago | bioprocessintl.com | Shreeyashi Ojha

Contract development and manufacturing organization (CDMO) National Resilience is constructing a 190,000 square-foot plant in Blue Ash, Ohio. This expansion will support operations at the West Chester plant by adding advanced automation for assembling and packaging drug products filled there. Additionally, the facility includes a cold and ambient storage space.
Cellares to open five facilities to support cell therapy tech

3 weeks ago | bioprocessintl.com | Shreeyashi Ojha

Self-proclaimed integrated development and manufacturing organization (IDMO) Cellares has confirmed the construction of five commercial-scale facilities across Europe and Japan. Though the locations of these facilities were not disclosed, the firm told BioProcess Insider that these cell therapy-focused “IDMO Smart Factories” will use robotics to produce up to ten times more batches at nearly half the cost, while its headquarters in San Francisco, California will support clinical trials.
FDA vaccine expert resigns, citing ‘irresponsible, detrimental’ RFK, Jr.

3 weeks ago | bioprocessintl.com | Søren Hough

Peter Marks, an oncologist physician who holds medical and research doctorates, was one of the leading Center for Biologics Evaluation and Research (CBER) figures at the US Food and Drug Administration (FDA). His work spanned cell and gene therapy and pandemic response efforts – particularly including vaccine development. Now, he’s resigned, and his public statement points the finger directly at Department Health and Human Services (HHS) Secretary Robert F.